CytoDyn Inc.

Name: CytoDyn Inc. standardized financial statements, quarterly
Creator: Listed

CYDYOTCCIK 1175680HealthcareFiscal year ends May 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$6.6m, Q1 FY2027

Net income−$19.9m, Q1 FY2027

CytoDyn Inc., income statement, quarterly
Line item	Unit	Q2 FY20242023-11-30	Q3 FY20242024-02-29	Q4 FY20242024-05-31	Q1 FY20252024-08-31	Q2 FY20252024-11-30	Q3 FY20252025-02-28	Q4 FY20252025-05-31	Q1 FY20262025-08-31	Q2 FY20262025-11-30	Q3 FY20262026-02-28	Q4 FY20262026-05-31	Q1 FY20272026-08-31
Revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	1.1	0.7	3.6	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$m	(3.4)	(3.4)	(6.6)	22.4	(3.7)	(4.0)	(5.1)	(4.9)	(21.7)	(6.3)	(5.6)	(6.6)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$m	(9.6)	(11.9)	(16.8)	19.2	(4.8)	(4.8)	(6.0)	(5.5)	(22.6)	(4.7)	(9.9)	(19.9)
Diluted EPS	$ per share	(0.01)	(0.01)	not reported	0.02	0.00	0.00	not reported	0.00	(0.02)	0.00	not reported	(0.01)
Basic EPS	$ per share	(0.01)	(0.01)	not reported	0.02	0.00	0.00	not reported	0.00	(0.02)	0.00	not reported	(0.01)

Balance sheet

Cash and equivalents$16.4m, Q1 FY2027

Long-term debt$35.8m, Q1 FY2027

Shareholders' equity−$98.1m, Q1 FY2027

CytoDyn Inc., balance sheet, quarterly
Line item	Unit	Q2 FY20242023-11-30	Q3 FY20242024-02-29	FY20242024-05-31	Q1 FY20252024-08-31	Q2 FY20252024-11-30	Q3 FY20252025-02-28	FY20252025-05-31	Q1 FY20262025-08-31	Q2 FY20262025-11-30	Q3 FY20262026-02-28	FY20262026-05-31	Q1 FY20272026-08-31
Cash and equivalents	$m	0.1	1.4	3.1	24.9	21.3	16.4	11.9	9.3	5.0	15.7	11.9	16.4
Current assets	$m	8.8	9.9	10.8	27.7	24.6	21.0	17.9	13.4	8.8	18.4	13.9	19.0
Total assets	$m	9.2	10.3	11.1	28.0	24.9	21.2	18.0	13.5	8.9	18.5	14.0	19.1
Current liabilities	$m	123	129	84.2	69.6	70.6	70.6	70.5	69.4	85.1	50.4	53.7	49.7
Total liabilities	$m	124	130	128	113	114	114	114	113	129	123	124	117
Long-term debt	$m	45.9	44.2	45.0	45.3	46.1	45.8	45.4	43.8	42.2	40.5	38.3	35.8
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(114)	(119)	(117)	(85.2)	(89.4)	(93.0)	(96.0)	(99.5)	(120)	(104)	(110)	(98.1)

Cash flow

Operating cash flow−$7.7m, Q1 FY2027

CytoDyn Inc., cash flow, quarterly
Line item	Unit	Q2 FY20242023-11-30	Q3 FY20242024-02-29	Q4 FY20242024-05-31	Q1 FY20252024-08-31	Q2 FY20252024-11-30	Q3 FY20252025-02-28	Q4 FY20252025-05-31	Q1 FY20262025-08-31	Q2 FY20262025-11-30	Q3 FY20262026-02-28	Q4 FY20262026-05-31	Q1 FY20272026-08-31
Operating cash flow	$k	(2,502)	(2,335)	(1,650)	5,440	(3,586)	(4,956)	(5,663)	(2,450)	(4,350)	(5,519)	(4,933)	(7,726)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)1.38bn, Q1 FY2027

CytoDyn Inc., shares, quarterly
Line item	Unit	Q2 FY20232022-11-30	Q3 FY20232023-02-28	Q1 FY20242023-08-31	Q2 FY20242023-11-30	Q3 FY20242024-02-29	Q1 FY20252024-08-31	Q2 FY20252024-11-30	Q3 FY20252025-02-28	Q1 FY20262025-08-31	Q2 FY20262025-11-30	Q3 FY20262026-02-28	Q1 FY20272026-08-31
Diluted shares (weighted)	m shares	813	832	924	959	982	1,198	1,221	1,228	1,253	1,261	1,275	1,382

Shares outstanding: 1.47bn at Sep 30, 2026, from the cover of the 10-Q filed Oct 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.